Regeneron's CEO Talks About His Drugs For Eye Disease, Cholesterol, And Asthma

But Eylea's success in the future will depend on Regeneron's ability to get the drug approved, and market it, for new uses, like treating eye problems caused by diabetes. And Regeneron's ability to prosper will depend on its ability to develop more drugs than just Eylea. As I detailed in the current issue of Forbes, chief scientist George Yancopoulos has built the company into a kind of futuristic factory for antibody medicines to treat high cholesterol, allergic skin rashes, and asthma. Can these lead Regeneron to further financial success? When I sat down with Regeneron CEO Leonard Schleifer recently, I asked him about each of these drug programs and their financial prospects. Below our his answers -- and further discussion -- on Eylea, on the cholesterol drugs called PCSK9 inhibitors, where Regeneron is in a dead heat with Amgen and Pfizer is close behind, and for the company's new experimental asthma medicine. Here are the videos.

Regeneron's CEO On The Eye Drug Market Eylea, for macular degeneration, was Regeneron’s first big hit. Can sales keep up?

[newsincvid id="25025227"]

The Cholesterol Drug Of The Future? Schleifer talks about the drug industry’s best target.

[newsincvid id="25025230"]

A Big Asthma Bet Does this drug target a common factor behind allergy and asthma?

[newsincvid id="25025232"]